4A-MPLA ammonium 

4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis^[1][2][3].

4A-MPLA (1.0 μg/mL; 24 h) ammonium induces a distinct cytokine profile in mouse bone-marrow-derived dendritic cells, with lower overall cytokine induction than 6A-DPLA but enhanced IFN-β production in MyD88-deficient mBMDCs^[1].
4A-MPLA (10-1000 nM) ammonium binds to the human TLR4-MD2 complex with high affinity, comparable to 6A-DPLA and significantly stronger than 3A-MPLA (HY-N16231) and 5A-MPLA^[1].
4A-MPLA ammonium drives a distinct transcriptomic signature in mouse bone-marrow-derived dendritic cells, strongly upregulating type I IFN and interferon-stimulated gene pathways^[1].
4A-MPLA (3-48 h post-treatment) ammonium induces a sustained Ifnb mRNA response in mouse bone-marrow-derived dendritic cells, with elevated expression remaining through 36 h post-treatment^[1].
4A-MPLA (15-90 min post-treatment) ammonium promotes robust TLR4 endocytosis in mouse bone-marrow-derived dendritic cells, inducing a ~30% loss of monomeric surface TLR4 by 30 min post-treatment^[1].
4A-MPLA (3-24 h post-treatment) ammonium induces sustained intracellular lipid droplet formation in mouse bone-marrow-derived dendritic cells; this formation is dependent on TLR4 and TRIF signaling and persists up to 24 h post-treatment^[1].
4A-MPLA ammonium-induced IFN-β production and TLR4 endocytosis in mouse bone-marrow-derived dendritic cells are dependent on Cdc42 and galectin-3 activity, as shown by dose-dependent inhibition with CASIN (HY-12874) (5-1000 nM) and anti-mGal-3 mAb (0.5-10 μg/mL)^[1].
4A-MPLA ammonium preferentially engages endosomal TLR4 in mouse bone marrow-derived dendritic cells, signals through TRIF, and induces a sustained IFNβ response^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4A-MPLA (20 μg/day; p.o.; daily; 4 days) ammonium pre-treatment potently protects against DSS (HY-116282)-induced colitis, reducing colitogenic IL-17A⁺ and IFN-γ⁺ CD4⁺ T cell populations in the colon^[1].
4A-MPLA (100 μg/mouse; p.o.; single dose) ammonium induces a sustained IFN-β response in colonic pDCs, with elevated production persisting for at least 18 hours in naive B6 SPF IFNβ1-EYFP reporter mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1326.76

C₆₈H₁₃₂N₃O₁₉P

2260669-09-6

O[C@@H]([C@@H]([C@H]([C@H](O1)O)NC(C[C@@H](CCCCCCCCCCC)O)=O)OC(C[C@H](O)CCCCCCCCCCC)=O)[C@H]1CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OP(O)(O)=O)O)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCCCCCCCCCC)=O)=O.N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cho HS, et al. Structure of gut microbial glycolipid modulates host inflammatory response. Cell. 2025;188(19):5295-5312.e18.  [Content Brief]

  [2]. Starling S. Commensal glycolipid structure shapes gut immunity. Nat Rev Microbiol. 2025 Oct;23(10):617.

  [3]. Zhang Y, et al. Diversity of oligosaccharides in lipooligosaccharides of Akkermansia muciniphila and its anti-atherosclerotic activity. Nat Prod Bioprospect. 2026;16(1):58. Published 2026 May 2.